Squarepoint’s Esperion Therapeutics ESPR Stock Holding History

Squarepoint’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-98,900	Closed	-$218K	–	4811
2024 Q4	$218K	Buy	+98,900	New	+$231K	﹤0.01%	4407

Other funds holding ESPR

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Squarepoint's ESPR Position: Q2 2026 in Review

Squarepoint sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 700,153 shares — an estimated $1.92M sold.

Squarepoint first reported a position in ESPR in Q2 2015 and held it in 31 quarters. The position peaked at $1.92M in Q1 2026. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Squarepoint reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
Squarepoint sold 700,153 Esperion Therapeutics shares in Q2 2026, an estimated $1.92M.
Squarepoint first reported a position in Esperion Therapeutics in Q2 2015 and held it in 31 quarters.
Squarepoint's Esperion Therapeutics position peaked at $1.92M in Q1 2026.
192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.